Skip to main content

Long-Acting Opioids Associated with Higher Mortality Risk

Prescription of long-acting opioids for chronic noncancer pain was associated with an increased risk of all-cause mortality, including deaths from causes other than overdose, compared with anticonvulsants or cyclic antidepressants, according to a study appearing in the June 14 issue of JAMA.

In a retrospective cohort study between 1999 and 2012, narcotic use among Tennessee Medicaid patients was assessed, specifically addressing cause-specific mortality.

The increase in prescribing opioid analgesics for chronic noncancer pain has led to escalating concern about potential harms. Long-acting opioids increase the risk of unintentional overdose deaths but also may increase mortality from cardiorespiratory and other causes. 

There were 22912 new episodes of prescribed long-acting opioids and control medications. The long-acting opioid group had 185 deaths and the control treatment group had 87 deaths.

The HR for total mortality was 1.64 (95% CI, 1.26-2.12) with a risk difference of 68.5 excess deaths (95% CI, 28.2-120.7) per 10 000 person-years. Increased risk was due to out-of-hospital deaths (HR 1.90).

The difference was explained by a 1.9 times greater risk of out-of-hospital deaths. More than two-thirds of the excess deaths were due to causes other than unintentional overdose; of these, more than one-half were cardiovascular deaths.

The risk of death was 4 fold higher in the first 30 days of therapy. Overall, the increased risk was higher to the first 180 days of prescribed therapy but was present for long-acting opioid doses of 60 mg or less of morphine-equivalents.

The authors warn that these findings should be considered when evaluating harms and benefits of using long-acting narcotics in the treatment of chronic, non-cancer pain.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject